Important note: Information in this article was accurate in May 2008. The state of the art may have changed since the publication date.
Tibotec issue Dear Doctor letter and FDA require darunavir label change relating to hepatotoxicity
HIV Treat Bull - 2008 May-June;9(5/6):26
Tibotec Dear Healthcare Professional
IMPORTANT DRUG WARNING, March 2008
Dear Healthcare Professional:
Tibotec Therapeutics, in cooperation with the U.S. Food and Drug Administration, would like to inform you of an important update to the prescribing information for darunavir (Prezista) tablets regarding addition of a warning on hepatotoxicity.
In clinical trials and postmarketing experience, drug-induced hepatitis (e.g., acute hepatitis, cytolytic hepatitis) has been reported in patients receiving combination therapy with darunavir/r. Given the clinical relevance of this adverse reaction, the following information on hepatotoxicity has been added to the WARNINGS section of the darunavir prescribing information:
Hepatotoxicity
Drug-induced hepatitis (e.g., acute hepatitis, cytolytic hepatitis) has been reported with darunavir/r. During the clinical development program (N=3063), hepatitis has been reported in 0.5% of patients receiving combination therapy with darunavir/rtv. Patients with preexisting liver dysfunction, including chronic active hepatitis B or C, have an increased risk for liver function abnormalities including severe hepatic adverse events.
Post-marketing cases of liver injury, including some fatalities, have been reported. These have generally occurred in patients with advanced HIV-1 disease taking multiple concomitant medications, having comorbidities including hepatitis B or C coinfection, and/or developing immune reconstitution syndrome.
A causal relationship with darunavir/r therapy has not been established.
Appropriate laboratory testing should be conducted prior to initiating therapy with darunavir/r and patients should be monitored during treatment. Increased AST/ALT monitoring should be considered in patients with underlying chronic hepatitis, cirrhosis, or in patients who have pretreatment elevations of transaminases, especially during the first several months of darunavir/r treatment.
If there is evidence of new or worsening liver dysfunction (including clinically significant elevation of liver enzymes and/or symptoms such as fatigue, anorexia, nausea, jaundice, dark urine, liver tenderness, hepatomegaly) in patients on darunavir/r, interruption or discontinuation of treatment must be considered.
In addition, the Adverse Reaction section of the darunavir prescribing information and the patient package insert have been updated to include this new information.
The new label, and supporting information are available online:
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6496
Source: FDA listserve http://www.fda.gov/oashi/aids/listserve/archive.html (12 March 09)http://www.fda.gov/oashi/aids/listserve/listserve2008.html#31208
2008-05-10
IB080905-22
©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.